Choksi Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Choksi Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹679 of operating cash. Higher than almost all Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 23% of its market value (net debt). Lower than 93% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 34% in 3 years, but profit fell: ₹11 less profit per ₹100 of extra sales. Lower than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹679Over the last 3 years, every ₹100 of reported profit came with ₹679 of operating cash.
Higher than almost all Healthcare companies in India.
Self-Funding Ratio
1.4×Over the last 3 years its own operating cash covered its investment spending (capex) 1.4 times.
Higher than 51% of Healthcare companies in India.
Cash Locked Ratio
₹12For every ₹100 of sales, ₹12 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹17 tied up three years earlier.
Less money tied up than 72% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
−₹11Sales grew 34% in 3 years, but profit fell: ₹11 less profit per ₹100 of extra sales.
Lower than 92% of Healthcare companies in India.
Asset Productivity Ratio
+34% / +19%In 3 years sales changed by +34% while total assets changed by +19%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.6×Debt due within a year is covered 0.6 times by its yearly operating cash.
Lower than 66% of Healthcare companies in India.
Cash Cushion Ratio
−23%Debt, after subtracting cash, equals 23% of its market value (net debt).
Lower than 93% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in India.
Tangible Net Worth Ratio
98%Of every ₹100 of net worth, ₹98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 61% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Choksi Laboratories Limited owes ₹0.64 for every ₹1 it owns. Net profit rose 29% in the year to Mar 2026, and shrank 15% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
67.3Investors pay ₹67.3 for every ₹1 of Choksi Laboratories Limited's yearly profit, higher than 79% of Healthcare companies in India.
P/B ratio
5.70The share price is 5.70 times Choksi Laboratories Limited's book value per share, higher than 63% of Healthcare companies in India.
Market cap
₹146 CrThe total market value of all of Choksi Laboratories Limited's shares at today's price (share price × number of shares), smaller than 94% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹26 CrWhat Choksi Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹36.72Net worth divided by the number of shares. The share price of ₹209.20 is 5.7 times this, which is the P/B above.
Return on equity (ROE)
8.5%Choksi Laboratories Limited earned 8.5% on its shareholders' money over the last year, lower than 74% of Healthcare companies in India.
Owes vs Owns
0.64×Choksi Laboratories Limited owes ₹0.64 for every ₹1 it owns (moderate), higher than 94% of Healthcare companies in India.
Dividend yield
NoneChoksi Laboratories Limited does not currently pay a dividend.
Revenue growth
+10%Revenue rose 10% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Profit growth
+29%Net profit rose 29% in the year to Mar 2026, and shrank 15% a year on average over 3 years.
Profit margin
4.3%Choksi Laboratories Limited keeps ₹4 of every ₹100 of revenue as net profit.
Cash quality
4.0×Cash from Choksi Laboratories Limited's business was 4.0× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
1.9×Choksi Laboratories Limited's operating profit covered its interest costs 1.9 times in the year to Mar 2026.
Cash vs debt
Net debtChoksi Laboratories Limited had ₹34 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Choksi Laboratories Limited's P/E ratio?
Investors pay ₹67.3 for every ₹1 of Choksi Laboratories Limited's yearly profit, higher than 79% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Choksi Laboratories Limited: ₹146 Cr ÷ ₹26 Cr (31 Mar 2026) = 5.7.
What is Choksi Laboratories Limited's return on equity?
Choksi Laboratories Limited earned 8.5% on its shareholders' money over the last year, lower than 74% of Healthcare companies in India.
How much does Choksi Laboratories Limited owe compared with what it owns?
Choksi Laboratories Limited owes ₹0.64 for every ₹1 it owns (moderate), higher than 94% of Healthcare companies in India.
Does Choksi Laboratories Limited pay a dividend?
No. Choksi Laboratories Limited does not currently pay a dividend.
Is Choksi Laboratories Limited's revenue growing?
Revenue rose 10% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.